查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602394

急性细菌性皮肤和结构性感染疾病市场：按感染类型、疾病类别、给药途径和分销管道分类 - 全球预测 2025-2030

Acute Bacterial Skin & Skin Structure Infection Market by Infection Type (Community-Acquired ABSSI, Hospital Acquired ABSSI), Disease Category (Nonpurulent, Purulent), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，急性细菌性皮肤和皮肤结构感染疾病市场估值为105.2亿美元，预计到2024年将达到113.5亿美元，复合年增长率为8.63%，到2030年预计将达到187.9亿美元。

急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 涉及皮肤和皮下组织的严重细菌侵入，包括蜂窝性组织炎、伤口感染和脓肿等病症。这些感染疾病可能会迅速进展并引起併发症，需要及时有效的医疗干预。 ABSSSI 在医疗保健领域发挥重要作用，增加了先进抗生素和治疗方法的需求。这些感染疾病的增加推动了对创新解决方案的需求，但它们的治疗主要在医院、诊所和门诊手术中心进行。市场动态是由抗药性细菌发生率增加、医学进步以及对新治疗方法认识不断增强等因素所驱动的。对新型抗生素不断增长的需求以及对更好诊断工具的需求带来了机会，开发更快、更准确的诊断技术和下一代抗生素具有巨大潜力。抓住这些机会的建议包括投资新型抗生素的研发、与生技公司建立策略伙伴关係以及利用最尖端科技进行快速诊断。然而，市场面临严格的监管途径、高昂的药物开发成本以及与抗生素治疗相关的潜在副作用等限制，这可能会抑製成长。旨在对抗细菌抗药性的严格抗生素管理计划使市场渗透更加复杂。最好的创新领域是联合治疗的开发以及寻找抗药性问题较少的天然或合成替代品。研究表明，製药公司和研究机构之间的合作对于推动突破性解决方案至关重要。该市场竞争激烈，其特点是持续的研究工作、不断变化的监管环境以及对具有成本效益的解决方案的需求。总体而言，技术创新对于解决 ABSSSI 未满足的需求至关重要，公司必须平衡监管合规性、经济可行性和有效的治疗结果，才能在这个不断发展的市场中取得成功。

主要市场统计
基准年[2023] 105.2亿美元
预测年份 [2024] 113.5亿美元
预测年份 [2030] 187.9亿美元
复合年增长率（%） 8.63%

市场动态：针对快速发展的急性细菌性皮肤和皮肤结构感染疾病市场揭示的关键市场见解

供应和需求的动态相互作用正在改变急性细菌性皮肤和皮肤结构感染疾病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 细菌性皮肤感染疾病的盛行率和案例不断增加
    • 提高人们对皮肤问题的认识
    • 皮肤科中心和诊所的增加
  • 市场限制因素
    • 与 ABSSSI 治疗相关的不良健康影响
  • 市场机会
    • 开发新药的持续研究开发活动
    • 临床权威机构的监管核准迅速增加
  • 市场问题
    • 缺乏标准通讯协定和不正确的治疗管理

波特的五力：驾驭急性细菌性皮肤和皮肤结构感染疾病市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解急性细菌性皮肤和皮肤结构感染疾病市场的外部影响

外部宏观环境因素在塑造急性细菌性皮肤和皮肤结构感染疾病市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解急性细菌性皮肤和皮肤结构感染疾病市场的竞争格局

对急性细菌性皮肤和皮肤结构感染疾病市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：急性细菌性皮肤和皮肤结构感染疾病市场供应商的绩效评估

FPNV 定位矩阵是评估急性细菌性皮肤和皮肤结构感染疾病市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製急性细菌性皮肤和皮肤结构感染疾病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对急性细菌性皮肤和结构性感染疾病市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 细菌性皮肤感染疾病的盛行率和病例不断增加
      • 提高人们对皮肤问题的认识
      • 皮肤科中心和诊所数量增加
    • 抑制因素
      • 与 ABSSSI 药物相关的不良健康影响
    • 机会
      • 开发新药的持续研究和开发活动
      • 临床权威机构的监管核准迅速增加
    • 任务
      • 缺乏标准通讯协定和治疗管理不充分
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章急性细菌性皮肤和皮肤结构感染疾病市场：依感染类型

  • 介绍
  • ABSSI 发生在社区
  • 院内ABSSI

第七章急性细菌性皮肤和皮肤结构感染疾病市场：依疾病类别

  • 介绍
  • 非化脓性
  • 化脓的

第八章急性细菌性皮肤和皮肤结构感染疾病市场：依给药途径

  • 介绍
  • 口服
  • 胃肠外的
  • 局部的

第九章急性细菌性皮肤和皮肤结构感染疾病市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第10章：美洲急性细菌性皮肤和皮肤结构感染疾病市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区急性细菌性皮肤和皮肤结构感染疾病市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章：欧洲、中东和非洲急性细菌性皮肤和皮肤结构感染疾病市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie, Inc.
  • Accord Healthcare Limited
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Basilea Pharmaceutica Ltd
  • BiVictriX Therapeutics PLC
  • Cadila Pharmaceuticals Limited
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm SA
  • Destiny Pharma PLC
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Innovation Pharmaceuticals Inc.
  • Intas Pharmaceuticals Ltd.
  • KBP Biosciences Co., Ltd.
  • Melinta Therapeutics, LLC
  • Merck & Co, Inc
  • MicuRx Pharmaceuticals, Inc.
  • Novartis International AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B16853776E4F

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 10.52 billion in 2023, expected to reach USD 11.35 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 18.79 billion by 2030.

Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involve serious bacterial invasion of skin and its underlying tissues, encompassing conditions like cellulitis, wound infections, and abscesses. These infections are critical due to their rapid progression and potential complications, demanding prompt and effective medical intervention. ABSSSIs hold crucial application in healthcare, driving the need for advanced antibiotics and therapies. Rising incidences of such infections fuel the necessity for innovative solutions, while their treatment primarily resides within hospitals, clinics, and ambulatory surgical centers. Market dynamics are propelled by factors like increasing incidence of drug-resistant bacteria, healthcare advancements, and heightened awareness around new treatment modalities. Opportunities arise from the growing demand for new antibiotics and the need for better diagnostic tools, with significant potential in developing faster and more accurate diagnostic technologies and next-generation antimicrobials. Recommendations for capturing these opportunities include investing in R&D for novel antimicrobial drugs, forming strategic partnerships with biotech firms, and leveraging cutting-edge technology for rapid diagnostics. However, the market faces limitations such as stringent regulatory pathways, high costs of drug development, and potential side effects associated with antibiotic treatments, which could dampen growth. Strict antibiotic stewardship programs to combat resistance further complicate market penetration. The best innovation areas lie in developing combination therapies and exploring natural or synthetic alternatives with fewer resistance issues. Insights suggest that collaborations between pharmaceutical companies and research institutions are essential to drive groundbreaking solutions. The market is competitive, characterized by ongoing research efforts, revolving regulatory landscape, and demand for cost-effective solutions. Overall, innovation will be crucial in addressing unmet needs in ABSSSIs, as companies need to balance between regulatory compliance, economic feasibility, and effective therapeutic outcomes to succeed in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 10.52 billion
Estimated Year [2024] USD 11.35 billion
Forecast Year [2030] USD 18.79 billion
CAGR (%) 8.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Bacterial Skin & Skin Structure Infection Market

The Acute Bacterial Skin & Skin Structure Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence and cases of bacterial skin infections
    • Increasing people awareness about skin problems
    • Growth in number of dermatology centers and clinics
  • Market Restraints
    • Associated adverse health impacts of ABSSSI drugs
  • Market Opportunities
    • Ongoing R&D activities for development of novel drugs
    • Surge in regulatory approvals from clinical authorities
  • Market Challenges
    • Lack of standard protocols and mismanaged treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acute Bacterial Skin & Skin Structure Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Bacterial Skin & Skin Structure Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Bacterial Skin & Skin Structure Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Bacterial Skin & Skin Structure Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Bacterial Skin & Skin Structure Infection Market

A detailed market share analysis in the Acute Bacterial Skin & Skin Structure Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Bacterial Skin & Skin Structure Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Bacterial Skin & Skin Structure Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Bacterial Skin & Skin Structure Infection Market

A strategic analysis of the Acute Bacterial Skin & Skin Structure Infection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Bacterial Skin & Skin Structure Infection Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Accord Healthcare Limited, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Basilea Pharmaceutica Ltd, BiVictriX Therapeutics PLC, Cadila Pharmaceuticals Limited, Cumberland Pharmaceuticals Inc., Debiopharm SA, Destiny Pharma PLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Innovation Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., KBP Biosciences Co., Ltd., Melinta Therapeutics, LLC, Merck & Co, Inc, MicuRx Pharmaceuticals, Inc., Novartis International AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Bacterial Skin & Skin Structure Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection Type, market is studied across Community-Acquired ABSSI and Hospital Acquired ABSSI.
  • Based on Disease Category, market is studied across Nonpurulent and Purulent.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence and cases of bacterial skin infections
      • 5.1.1.2. Increasing people awareness about skin problems
      • 5.1.1.3. Growth in number of dermatology centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Associated adverse health impacts of ABSSSI drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for development of novel drugs
      • 5.1.3.2. Surge in regulatory approvals from clinical authorities
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standard protocols and mismanaged treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

  • 6.1. Introduction
  • 6.2. Community-Acquired ABSSI
  • 6.3. Hospital Acquired ABSSI

7. Acute Bacterial Skin & Skin Structure Infection Market, by Disease Category

  • 7.1. Introduction
  • 7.2. Nonpurulent
  • 7.3. Purulent

8. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Acute Bacterial Skin & Skin Structure Infection Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Bacterial Skin & Skin Structure Infection Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Bacterial Skin & Skin Structure Infection Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Accord Healthcare Limited
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Aurobindo Pharma Limited
  • 5. Basilea Pharmaceutica Ltd
  • 6. BiVictriX Therapeutics PLC
  • 7. Cadila Pharmaceuticals Limited
  • 8. Cumberland Pharmaceuticals Inc.
  • 9. Debiopharm SA
  • 10. Destiny Pharma PLC
  • 11. Fresenius SE & Co. KGaA
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Limited
  • 14. Innovation Pharmaceuticals Inc.
  • 15. Intas Pharmaceuticals Ltd.
  • 16. KBP Biosciences Co., Ltd.
  • 17. Melinta Therapeutics, LLC
  • 18. Merck & Co, Inc
  • 19. MicuRx Pharmaceuticals, Inc.
  • 20. Novartis International AG
  • 21. Paratek Pharmaceuticals, Inc.
  • 22. Pfizer Inc.
  • 23. Sun Pharmaceutical Industries Limited
  • 24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COMMUNITY-ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL ACQUIRED ABSSI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NONPURULENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PURULENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023